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Abstract
Background: Psoriasis is a chronically recurrent inflammatory skin disease, modern medicine could achieve good
therapeutic effect, but these treatments led to recurrence of the psoriasis, more severe symptoms due to damaging
skin barrier. Traditional Chinese medicine is a useful alternative therapies. The purpose of this study was to explore
the mechanism of PSORI-CM01, a Chinese medicine formula for psoriasis therapy, in eliminating psoriasis by
studying its effects on inhibiting epidermal hyperplasia.
Methods: Imiquimod induced psoriasis-form mice model was used to determine the efficacy of PSORICM-01 by
assessing the improvement of hyperplasia in epidermal and dermal skin, cyclin B2 expression in skin was detected
by immunochemistry. Human keratinocyte cell line HaCaT stimulated by LPS or not was used to research molecular
mechanisms of PSORIMCM-01 as in vitro model. The inhibition of proliferation of HaCaT was determined by MTT
assay, BrdU assay and real-time cell analysis (RTCA). Cell cycle distribution was detected by flow cytometry. Real-
Time PCR and western blot analysis was performed to quantify the mRNA and protein expression levels,
respectively. The ability of PSORICM-01 to inhibit proliferation of cyclin B2 overexpressed HaCaT cell were also
investigated.
Results: PSORI-CM01 significantly inhibited epidermal hyperplasia in IMQ mice lesion skin, and reduced expression
of epidermis cyclin B2. Serum containing PSORI-CM01 dramatically inhibited keratinocyte HaCaT cell proliferation,
no matter stimulated by LPS or not. FACS analysis showed ability of PSORICM-01 to arrest cell cycle in the G2/M
phase. Additionally, PSORI-CM01 significant downregulated mRNA and protein expression of cyclin B2, and over-
expression of cyclin B2 antagonized the anti-proliferative effect of PSORI-CM01 on HaCaT cells.
Conclusions: PSORI-CM01 inhibits epidermal hyperplasia in imiquimod-induced mouse psoriasis-form model and
reduces keratinocyte proliferation in vitro. Our results indicate that PSORI-CM01 may possess therapeutic potential
for psoriasis by inhibiting keratinocyte proliferation through downregulation of cyclin B2.
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Background
Psoriasis is a chronically recurrent inflammatory skin
disease that is characterized by keratinocyte hyperplasia,
inflammatory cell infiltration into the dermis and neo-
vascularization. The symptoms commonly include a
reddish scaly rash with itching and flaking skin. In gen-
eral, psoriasis is induced by multiple factors, such as
autoimmunity, environment and infection. This disease
is estimated to affect 2–3 % of the general population
worldwide [1]. Currently, topical agents such as Calcipo-
triol, combination of Betamethasone, and systemic medi-
cation treatment, et al., were used to treat psoriasis, and
could achieve good therapeutic effect. But, all these
treatments would damage skin barrier, and led to recur-
rence of the psoriasis, some even with more severe
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symptoms. Traditional Chinese medicine is a useful al-
ternative therapies.
PSORI-CM01, a Chinese medicine formula for psoria-
sis therapy, composed of Curcuma zedoaria, Sarcandra
glabra, DarkPlumFruit, Rhizoma Smilacis Glabrae,
Lithospermum erythrorhizon, Paeonia lactiflora, Glycyr-
rhiza uralensis, is derived from a prescription invented
by Xuan Guowei, a nationally renowned dermatologist
in the Guangdong Provincial Hospital of Chinese medi-
cine. It has been used to treat psoriasis for more than
20 years without significant side effects. And a trial on
effect of PSORI-CM01 in patients with psoriasis was car-
ried out, and the results showed that reduction rate of
PASI50 (psoriasis area and severity index) of psoriasis
patients after PSORI-CM01 treatment is 61 % (25/41)
[2]. Furthermore, proliferation and activation of kerati-
nocytes affects the occurrence and development of psor-
iasis. So in the present study, we investigated the
mechanism of PSORI-CM01 in eliminating psoriasis by




Tissue Freezing Medium was obtained from SAKURA
(Alphen aan den Rijn, NL), Lipopolysaccharide (LPS), me-
thyl thiazolyl tetrazolium (MTT) and dimethyl sulfoxide
(DMSO) were obtained from SIGMA-ALDRICH (St. Louis,
MO, USA). α-MEM medium and foetal bovine serum were
obtained from GIBCO (GRAND ISLAND, NY, USA). The
Elisa kit and BrdU used to measure cell proliferation were
from Roche Diagnostics, (Mannheim, Germany), the RT re-
agent kit and SYBR ® Premix Ex Taq ™ II were from
TAKARA (DaLian, Liaoning, China), the RIPA buffer and
GAPDH rabbit mAb were from Cell Signaling Technology
(Beverly, MA, USA), the BCA Protein Assay Kit was from
Thermo Scientific (Wilmington, DE, USA), the Cyclin B2
(CCNB2) rabbit polyclonal IgG was from Santa Cruz (Dal-
las, TX, USA), the Goat anti-rabbit IgG-HRP was from
CALBIOCHEM (Merck KGaA, Darmstadt, Germany), the
Cellular DNA content detection kit was from Keygen bio-
tech (NanJing, Jiang Su, China), and pEZ-CCNB2 (Expres-
sion Clone of Homo sapiens cyclin B2) and pEZ-CTRL
(Negative control of Expression Clone) were Fulengen
(Guangzhou, GuangDong, China). Lipofectamine ® LTX &
PLUS ™ Reagent was from Life Technologies (Grand Island,
NY, USA), and PureYield ™ Plasmid Midiprep System was
from Promega (Madison, WI, USA). The imiquimod cream
was from Sichuan MingXin Pharmaceutical Company, LTD
(Chengdu, Sichuan, China), the Compound Glycyrrhizin
Tablets (CGT) were from Akiyama Tablet (Shinagawa-ku,
Tokyo, Japan), and the Acitretin Capsules were from
Chongqing Win Bond Pharmaceutical Company, LTD
(Chongqing, China).
Animals and cellls
All animals, BALB/c mice (20–22 g), were fed on a
standard diet, had free access to water and were housed
under standard laboratory conditions.
HaCaT cells, an immortalized epidermal keratinocyte
cell line, were cultured in MEMα medium containing
10 % FBS in a 37 °C tissue culture incubator with 5 %
CO2 (Thermo Scientific, 310, DE, USA).
PSORI-CM01 tablet and its quality
PSORI-CM01 is mainly composed of Curcuma zedoaria,
Sarcandra glabra, DarkPlumFruit, Rhizoma Smilacis
Glabrae, Lithospermum erythrorhizon, Paeonia lactiflora,
Glycyrrhiza uralensis, and their ratio is 3:5:5:5:2:3:2.
PSORI-CM01 tablets were derived from PSORI-CM01
extract in the Guangdong Provincial Hospital of Chinese
medicine.
The quality standards of PSORI-CM01 extract are as
follows. Briefly, chromatography analysis was performed
using an Agilent Technologies 1100 series system (Ber-
ryville, Virginia, United States) equipped with a UV de-
tector and a Kromasil 100–5 C18 column. The mobile
phase consisted of 100 % methyl alcohol and 0.1 % acetic
acid. The gradient program was as follows: 0–10 min,
(10:90–30:70); 10–40 min, (30:70–40:60). The flow rate
was 1.0 ml/min. The eluted compounds were identified
by standards, and were detected by characteristic peak
area. Isofraxidin, liquiritin and astilbin were detected at
320 nm, and paeoniflorin was detected at 230 nm at
room temperature. The injection volume was 10 μL. The
contents of the tablets were as follows: 1, paeoniflorin
about 0.281 mg/g dried medicinal herbs; 2, isofraxidin
about 0.133 mg/g dried medicinal herbs; 3, liquiritin
about 0.445 mg/g dried medicinal herbs; 4, astilbin about
1.202 mg/g dried medicinal herbs.
Preparation and quality of PSORI-CM01-containingserum
Blank serum and PSORI-CM01-containingserum (here
after referred to as PSORI-CM01 serum) were derived
from 20 SPF SD rats weighing from 220–250 g that were
purchased from Guangdong Medical Laboratory Animal
Centre. Rats were given food water ad libitum and were
housed at room temperature of 20–22 °C. The animals
were randomly assigned into 2 groups: the control
group, receiving saline, and the treatment group, receiv-
ing a PSORI-CM01 decoction. PSORI-CM01 was ad-
ministered by gavage, and the rats received 38.6 g crude
drug/kg body weight, 2 times daily for 5 days. Food was
withdrawn from the rats 12 h before the last gavage, and
blood was drawn from the celiac artery under 10 %
chloral hydrate anaesthesia 1.5 h after the last gavage.
Blood samples were left at room temperature for 6 h
and then centrifuged at 3500 rpm for 15 min. The
supernatant was collected and sterile-filtered using a
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0.22 μm filter. Lastly, the blood samples were frozen at-
30 °C.
The quality standards of the PSORI-CM01-containing
serum are as follows. Briefly, chromatography of PSORI-
CM01-containing serum was performed using an Agi-
lent Technologies 1100 series system equipped with a
UV detector and a Phenomenex C18 column. The mo-
bile phase consisted of 100 % methyl alcohol (B), 100 %
acetonitrile (C) and 0.05 % formic acid (D). The gradient
program was as follows: 0–5 min, B-C-D (20:5:75)-B-C-
D (30:5:65); 5–10 min, B-C-D (30:5:65)-B-C-D
(35:10:55); 10–20 min, B-C-D (35:10:55)-B-C-D
(40:10:50). The flow rate was 0.8 ml/min, and the eluted
compounds were identified by standards, and were de-
tected by characteristic peak area at 275 nm at room
temperature. The injection volume was 10 μL. The con-
tents of the PSORI-CM01-containing serum are as fol-
lows: 1, paeoniflorin approximately 31.15 ug/mL; 2,
isofraxidin approximately 1.07 ug/mL; 3, liquiritin ap-
proximately 1.43 ug/mL; 4, astilbin approximately 5.35
ug/mL; 5, rosmarinic acid approximately 9.27 ug/mL.
Mouse model of psoriasis induced by imiquimod
Mice were anesthetized with 200 μl 0.6 % sodium pento-
barbital, and the hair was shaved in a 1.5 cm × 2 cm spot
on the back. Mice in all groups except for WT had
50 mg imiquimod (IMQ) smeared onto the shaved areas
everyday during the first 2–7 days and every other day
for the following 8–20 days. The body weights of the
mice were recorded daily.
Assessment of epidermal hyperplasia
BALB/c mice were randomly divided into 6 groups with
10 mice per group: Normal mice without psoriasis in-
duced by imiquimod (WT); imiquimod (IMQ)-induced
mice with saline treatment (NS); IMQ-induced mice re-
ceiving 6.88 mg/day glycyrrhizin by gavage (CGT); IMQ-
induced mice receiving12.5 mg/day PSORI-CM01 tablets
(T1); IMQ-induced mice receiving25.0 mg/day PSORI-
CM01 tablets (T2); IMQ-induced mice receiving
50.0 mg/dayPSORI-CM01 tablets (T3). According to the
treatment, mice in the 5 groups were administered with
400 μl vehicle or drug solution by daily oral gavage from
8–20 days.
On day 20, mice were sacrificed by cervical disloca-
tion, and the back skin was collected and blocked in par-
affin for hematoxylin-eosin (HE) staining to observe
pathological features. Pictures were taken after the stain-
ing, and the skin area in the same width was calculated
according to the area formula = pixels/(horizontal reso-
lution × vertical resolution) using a Zeiss Axio Scope
A1microscope (Carl Zeiss, Oberkochen, Germany) using
Axio Vision software.
Immunohistochemistry of epidermis
After antigen retrieval and inactivation of endogenous
peroxidase activity, tissue sections were incubated with
Cyclin B2 antibody overnight at 4 °C. After washing, the
sections were incubated with biotinylated goat anti-
rabbit IgG, followed by incubation with a solution of
avidin-conjugated horseradish peroxidase. Peroxidase ac-
tivity was detected using H2O2/diaminobenzidine sub-
strate solution. The slides were counterstained with
hematoxylin solution for 1 min. After dehydration, the
tissue was sealed with a universal mount. Controls were
prepared in the same manner as detailed for the experi-
mental group, except for the incubation process with
primary antibody.
MTT assay
Cells in the exponential growth phase were seeded at a
density of 4,000 cells per well in 96-well plates with
200 μL medium/well. Blank serum or PSORI-CM01-
containing serum was added after stimulation by LPS.
20 μL MTT solution (5 mg/ml) was added to each well
at the detection time points and incubated for 4 h. The
formazan crystals were dissolved with 100 μL DMSO.
After all the purple formazan crystals was completely
dissolved, the OD value of each well was detected in a
Multilabel reader (PerkinElmer, 2030) at a 570 nm
wavelength.
BrdU assay
Results were obtained from 6 separate experiments. Cells
in the exponential growth phase were seeded at a density
of 4,000 cells/well into 96-well plates with 100 μL
medium/well. BrdU was used at a final concentration of
10 μM. BrdU and PSORI-CM01-containingserum were
added simultaneously with lipopolysaccharide (LPS), and
cells were incubated for 16 h. Medium was removed, and
200 μl fixative was added per well. 30 min later, the fixa-
tive was removed, and the anti-BrdU-working fluid was
added at room temperature for approximately90min.
After washing with PBS,100 μl of the chromogenic sub-
strate was added to each well for 15 min. 25 μl of the stop
solution was added to each well, and the absorbance at
450 nm was measured using a Multilabel reader (PekinEl-
mer, 2030, MA, USA).
RTCA assay
The xCELLigence RTCA system (ACEA, DP, CA, USA)
was used to monitor cell viability by measuring the Cell
Index (CI) transformed by the electrical impedance be-
tween the cell surface and the bottom electrode plate.
The CI value is positively correlated with the number of
cells and cell vitality. Briefly, cells in the exponential
growth phase were seeded at a density of 4,000 cells per
well in E-Plate 16 plates with 200 μL medium/well. Data
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were collected every 30 min, and the total monitoring
time was 100 h.
Analysis of cell cycle
The cells were digested with 0.25 % Trypsin, centrifuged,
then fixed in cold 70 % ethanol overnight at-20 °C. The
cells were washed with cold PBS and re-suspended to a
density of 1.0 × 106 cells/ml. 100 μL RNase A was added
into 100 μl cell suspension, and incubated at 37 °C for
30 min. Then, 400 μL PI staining solution was added
and incubated at 4 °C in dark for 30 min. Finally, red
fluorescence distribution was detected at the 488 nm
wavelength in the flow cytometry (Beckman Coulter/
FC500 Boulevard Brea, CA, USA).
Real-time PCR analysis
Total RNA was extracted with TRIZOL reagent accord-
ing to the manual. A spectrophotometer (Thermo Scien-
tific/NANOdrop 2000, DE, USA) was used to determine
the concentration and purity of total RNA by measuring
the 260 nm/280 nm absorbance ratio. cDNA synthesis
was performed with a PrimeScriptTM RT reagent kit ac-
cording to the manufacturer’s instructions. The volume
of the qPCR reactions was 20 μL (2 μl template, 200 nM
primers), and each sample was detected in duplicate.
The reaction conditions were determined in accordance
with SYBR Premix Ex TaqTM reagent instructions, and
the melting curves were analysed for production specifi-
city in a Real Time PCR system (ABI, 7500, NY, USA).
Primers are shown in detail in Table 1.
Western blot
The cells were collected and lysed in lysis buffer on ice,
and the protein concentration was measured using a
BCA Protein Assay Kit according to the manufacturer’s
instructions. The concentration of protein was adjusted
to 2 μg/μL with sterile water. For the western blot, the
Cyclin B2 IgG primary antibody were diluted 1:1000,
and the goat anti-rabbit IgG-HRP secondary antibody
were diluted 1:10,000 before incubation. chemilumines-
cence was added prior to exposure of the blot to detect
the targeted protein.
Over-expression of Cyclin B2
The cyclin B2 over-expressing plasmid pEZ-CCNB2 was
transformed DH5α, then it was cultured in the LB
medium with Ampicillin for screening. PureYield ™ Plas-
mid Midiprep System was used to purify pEZ-CCNB2,
then it was transfected into HaCaT cells with Lipofecta-
mine ® LTX & PLUS. Next, cyclin B2 expression level in
the HaCaT cells was detected by Real-time PCR and
western blot.
Statistical analysis
Statistical data analysis was performed using GraphPad
Prism 5, and the results are expressed as the mean ± SD.
Differences between two groups were compared using
Student’s t test, and P < 0.05 indicated a statistically sig-
nificant difference. Image data are only used to illustrate
the trends.
Results
PSORI-CM01 tablets reduce loss of body weight
The body weight of the NS group diminished through-
out the experimental period, whereas the body weights
of the T1, T2 and T3 treatment groups remained more
consistent. The effect of PSORI-CM01 is similar to that
of glycyrrhizin in the positive control group (CGT), indi-
cating that the drug therapy improved the overall state
of the mice. Detailed results are presented in Fig. 1.
PSORI-CM01 tablets suppressed epidermal hyperplasia
Typical psoriasis symptoms such as layered scales, ery-
thema, skin wrinkles and thickness were observed in the
Imiquimod-induced mouse model of psoriasis. After
treatment with PSORI-CM01 tablets, significant changes
in skin wrinkles and thickness were observed (P < 0.05).
Compared with the NS control group, the damaged skin
areas of the T1, T2, T3 mice were significantly decreased
(P < 0.05), and the effect of PSORI-CM01 tablets was
similar to that of the positive control group treated with
Glycyrrhizin tablets (Fig. 2a, b). These results showed
that PSORI-CM01 tablets significantly inhibited epider-
mal hyperplasia in the Imiquimod-induced mouse model
of psoriasis.
Table 1 Primers applied in the experiments
gene primer (F/R) bp
CCNB1 TCTGGATAATGGTGAATGGACA; CGATGTGGCATACTTGTTCTTG 157
CCNA2 AGCTGCCTTTCATTTAGCACTCTAC; TTAAGACTTTCCAGGGTATATCCAGTC 93
CCNB2 TTGCAGTCCATAAACCCACA; GAAGCCAAGAGCAGAGCAGT 218
CCNB3 GAACCAGCCCAAATGTGTCT; ACAACTCCTTCCCAGTGGTG 162
TGFb1 AGGGCTACCATGCCAACTTC; CCCGGGTTATGCTGGTTGTA 103
GAPDH GGTCTCCTCTGACTTCAACA; AGCCAAATTCGTTGTCATAC 116
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PSORI-CM01 tablets reduced expression of cyclin B2 in
the epidermis
The normal mouse epidermis (WT group) expresses a
very low level of cyclin B2. However, the mice in the NS
group exhibited an upregulation of cyclin B2 in the epi-
dermis compared with the WT group. Cyclin B2 expres-
sion in the epidermis of mice in theT1 group, T2 group
andT3 group had a lower staining intensity and fre-
quency compared with that in NS group. The T1 group
had the lowest cyclin B2 expression. These results indi-
cate that the PSORI-CM01 tablet inhibited the expres-
sion of epidermal cyclin B2 in the Imiquimod-induced
mouse model of psoriasis. Representative images of im-
munohistochemical staining of cyclin B2 are presented
in Fig. 3.
PSORI-CM01 inhibited the growth of HaCaT cells
As shown in Fig. 4a, the MTT assay results revealed
that the HaCaT cell proliferation was significantly
inhibited by PSORI-CM01-containing serum, if the
concentration of PSORI-CM01 was above 16 % in the
serum (P < 0.05). As shown in Fig. 4b and c, the
MTT and BrdU assays indicated that the proliferation
of LPS-stimulated HaCaT cells was also remarkably
inhibited by PSORI-CM01-containing serum (P < 0.05).
However, the RTCA assay revealed that PSORI-CM01-
containing serum inhibited LPS-stimulated HaCaT cell
proliferation, and the inhibition lasted more than
25 h, with the most significant inhibitory effect occur-
ring from 8 h point to 25 h point shown in Fig. 4d
(P < 0.05).
Fig. 1 Effect of PSORI-CM01 tablets on body weight in a mouse model of parapsoriasis induced by imiquimod
Fig. 2 Effect of PSORI-CM01 tablets on epidermal hyperplasia in the mouse model of parapsoriasis induced by imiquimod. a Representative HE
staining for morphological examination of mouse skin. 400 μl of NS, or 6.88 mg/d CGT, as well as 12.5 mg/d, 25.0 mg/d or50.0 mg/d PSORI-CM01
tablets were administered orally to mice for 12 days after 8 days of imiquimod treatment. Images were captured at 100× (objective lenses 10 ×)
under a light microscope using Axio Vision software (Carl Zeiss) at room temperature. b Histological sections of the epidermis on day 20 after the
first imiquimod treatment, statistical analysis shows the epidermis area relative to the WT group for each group (WT group = 1, *P < 0.05 vs. NS
group, n = 20)
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PSORI-CM01 induced cell cycle G2/M phase arrest
We determined the cell cycle distribution of HaCaT cells
at different times (6 h, 9 h, 12 h, 15 h, 18 h and 24 h)
after treatment with PSORI-CM01-containing serum. As
shown in Fig. 5, the results showed a significant arrest of
the cell cycle in the G2/M phase both at 6 h and 9 h.
Compared with the blank serum, PSORI-CM01-
containing serum dramatically decreased the proportion
of cells in the G0/G1 phase (P < 0.05) and increased the
proportion of cells in the G2/M phase (P < 0.05), while
there was no significant effect on the S phase. These
results suggest that inhibition of cell proliferation in
LPS-stimulated HaCaT cells may be associated with the
induction of cell cycle arrest in the G2/M phase.
Fig. 3 Effect of PSORI-CM01 tablets on cyclin B2 in representative epidermis from each group. magnification ×100. Representative HE staining for
morphological examination of mouse skin. 400 μl of NS or 6.88 mg/d CGT were administered orally as a negative and positive control, respectively.
12.5 mg/d, 25.0 mg/d or 50.0 mg/d PSORI-CM01 tablets were administered orally to mice for 12 days after 8 days of imiquimod induction. Images were
acquired at 100 × (objective lenses 10 ×) on a light microscope using Axio Vision software (Carl Zeiss) at room temperature
Fig. 4 Anti-proliferative effect of PSORI-CM01-containing serum on HaCaT cell proliferation in vitro a HaCaT cells without LPS stimulation were
incubated with various concentrations of blank or PSORI-CM01-containing serum (8 %, 12 %, 16 % and 20 % by volume) for 24 h, then viability
was measured using an MTT assay, analysed by measuring the absorbance at 570 nm. b HaCaT cells stimulated with 10 μg/ml LPS were
incubated with 16 % blank or PSORI-CM01-containing serum for 24 h, then viability was measured using an MTT assay (* P < 0.05). c HaCaT cells
stimulated with10μg/ml LPS were incubated with 16 % blank or PSORI-CM01-containing serum for 15 h, then viability was measured using a BrdU
assay, analysed by measuring the absorbance at 450 nm (* P < 0.05). d HaCaT cells stimulated with10μg/ml LPS were incubated with 16 % blank or
PSORI-CM01-containing serum, and then the cell index was measured using the RTCA assay (* P < 0.05, each time point during indicated period)
Wei et al. BMC Complementary and Alternative Medicine  (2016) 16:255 Page 6 of 10
PSORI-CM01 inhibited gene expression and protein level
of Cyclin B2
Because PSORI-CM01-containing serum arrested HaCaT
cells in the G2/M phase, we explored the effects of
PSORI-CM01-containing serum on the expression of cell
cycle-related gene, including cyclin A2 (CCNA2), cyclin
B1 (CCNB1), cyclin B2 (CCNB2), cyclin B3 (CCNB3) and
transforming growth factor-beta (TGF-β). Although no re-
markable change was observed in the expression of
CCNA2, CCNB1, CCNB3 or TGF-β (P > 0.05), PSORI-
CM01-containing serum significantly inhibited CCNB2
mRNA expression in HaCaT cells stimulated by LPS
(Fig. 6a, P < 0.05). As shown in Fig. 6b, PSORI-CM01-
containing serum significantly inhibited the protein level
of CCNB2 in LPS-stimulated HaCaT cells at different
times.
Overexpressed cyclinB2 reversed inhibitory effect of
PSORI-CM01 on the proliferation of HaCaT cells
Compared to the pEZ-CTRL transfected control group,
the pEZ-CCNB2-transfected HaCaT cells had approxi-
mately 4.0-foldhigher mRNA expression (Fig. 7a) and
50 % higher protein expression of cyclin B2. The results
of the BrdU assay indicated that PSORI-CM01-
containing serum significantly inhibited the proliferation
of HaCaT cells transfected with pEZ-CTRL plasmids in
LPS-stimulated HaCaT cells (P <0.05). However, PSORI-
CM01-containing serum did not significantly inhibit the
proliferation of LPS-stimulated HaCaT cells transfected
withpEZ-CCNB2, as shown in Fig. 7b. These results sug-
gest that overexpression of CCNB2 may reverse the in-
hibition of PSORI-CM01-containing serum on the
proliferation of HaCaT cells.
Discussion
Psoriasis is a chronic inflammatory skin disease charac-
terized by leukocyte infiltration in the dermis and epi-
dermis, keratinocyte hyper-proliferation, and dilatation
and growth of blood vessels. Despite the introduction of
new biological therapies has revolutionized the treat-
ment of psoriasis, however, biologics do not cover the
needs of those patients whose psoriasis is not severe
enough to warrant their use.
PSORI-CM01 is an effective Chinese medicine formula
in patients with psoriasis vulgaris. A clinical trial on the
formula was carried out in 22 patients with psoriasis vul-
garis. The patients were treated with PSOR1-CM01 for-
mula orally, and the observation lasted 2 months. The
psoriasis area and severity index (PASI), dermatology life
quality index (DLQI) and adverse events were recorded.
Compared with those before treatment, PASI scores
were significantly decreased after treatment, and DLQI
Fig. 5 Effects of PSORI-CM01-containing serum on cell cycle. HaCaT cells were stimulated with10μg/ml LPS prior to the addition of 16 % blank or
PSORI-CM01-containing serum for 6 h. Cell cycle distribution was measured by flow cytometry. a-c) Representative image of PI staining by flow
cytometry. d The cell cycle distribution was quantified in HaCaT cells (with or without LPS stimulation) treated with 16 % blank or PSORICM01-
containing serum (*P < 0.05)
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score decreased by 12 % after treatment. No adverse
events occurred during the observation. So PSOR1-
CM01 formula is considered to be safe and effective for
the treatment of psoriasis vulgaris [3], but its mechanism
is still unclear.
In the present study, we sought to determine the
antipsoriatic properties of Psoricm01, a Chinese medi-
cine that is used for psoriasis vulgaris in Southern
China by oral administration, and preliminary clarified
its molecular mechanisms. Topical administration of
IMQ, a ligand for Toll-like receptors 7 and 8, was re-
ported as a novel mouse model of psoriasis and was
used to research pesticide effects and mechanisms of
antipsoriatic drugs [4] In this model, mice adminis-
trated with PSORI-CM01 tablets had a little loss of
body weight compared with the mice in IMQ model
group, and Psori-cm01 was also able to ameliorate
the course of the disease, resulting in normalization
of skin inflammation and keratinocyte proliferation.
Then, HaCaT cell line was used as a in vitro tool to
justifies the ability of drug serum which contained
Psori-CM01 (PSORI-CM01-containing serum) to prevent
keratinocyte proliferations. We observed PSORI-CM01-
containing serum could obviously inhibit cell proliferation
no matter the HaCaT cells were stimulated by LPS or not,
when compared with rat control serum.
To further clarify the mechanism of Psori-CM01
growth inhibition, its ability to arrest cell cycle has
been studied. The results of FACS analysis showed
ability of Psori-CM01 to arrest cell cycle in the G2/M
phase. The arrest of cell cycle progression in the G2/
M phage is mainly regulated by the maturation pro-
moting factor (MPF). MPF is composed of cyclin B
and cyclin-dependent kinase 1 (CDK1). Cyclin B is a
key regulated unit that changes cyclically and reaches
a peak in expression during the G2/M phase that
abruptly diminishes after M phase. While CDK1 ac-
tivity is dependent on the concentration of cyclin B
[5, 6]. In general, inhibition of proliferation and cycle
arrest in the G2/M phase is due to the reduction of
cyclin B. There are 3 subtypes in cyclin B family,
named cyclinB1 (CCNB1), cyclin B2 (CCNB2), and
cyclin B3 (CCNB3). We found LPS could enhance
Fig. 6 The effects of PSORI-CM01-containing serum on the mRNA
expression and protein level of cyclin B2 in LPS- stimulated HaCaT cells.
a HaCaT cells stimulated with 10 μg/ml LPS were incubated with 16 %
blank or PSORI-CM01-containing serum for 6 h or 9 h, then mRNA
expression was measured by real-time PCR. b LPS-stimulated HaCaT
cells were incubated with 16 % blank or PSORI-CM01-containing serum
for different times prior to western blot analysis of cyclin B2 expression
Fig. 7 The effects of overexpressed CCNB2 on the proliferation of
HaCaT cells treated with PSORI-CM01-containing serum. a CCNB2
mRNA was raised significantly in pEZ-CCNB2-transfected HaCaT
cell (P<0.05 vs pEZ-CTRL). b Treatment with PSORI-CM01-containing
serum resulted in significant inhibition of the proliferation of pEZ-
CTRL-transfected HaCaT cells stimulated with 10 μg/ml of LPS,how-
ever, there was no significant inhibition of proliferation of pEZ-
CCNB2-transfected HaCaT cells stimulated with 10 μg/ml of LPS
(* P < 0.05)
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CCNB2 mRNA and protein expression in HaCaT cells
and Psori-CM01-contained serum could reduce
CCNB2 expression both in mRNA and protein level.
To verify the target of Psori-CM01 on HaCaT cell was
CCNB2 or not, we further constructed plasmid pEZ-
CCNB2 and pEZ-control, transfected to HaCaT cells,
and evaluate cell viability stimulated by LPS or not. We
found Psori-CM01-contained-serum could not inhibit
the hyper-proliferation of HaCaT cells which transfected
with pEZ-CCNB2 and stimulated by LPS, meanwhile
under the stimulation of LPS, the drug serum showed
obviously anti-proliferation effect on HaCaT cells which
transfected with pEZ-CTRL plasmid. Our results indi-
cate that inhibit proliferation effect of Psori-CM01-
contained-serum on HaCaT cell maybe related to kera-
tinocyte CCNB2 expression. We also detected CCNB2
expression in IMQ mice skin lesion by IHC. CCNB2 was
more expressed in psoriasis-form skin especially in the
mice epidermis when compared with WT group, while
mice administrated with Psori-CM01 had a lower ex-
pression of CCNB2 in epidermis. The results showed
that CCNB2 abnormally expression maybe associated
with IMQ induced psoriasis-form pathological lesion,
and Psori-CM01 could inhibit the expression of CCNB2
both in the epidermis in IMQ model in vivo, and in LPS
induced HaCaT cell hyper-proliferation model in vitro.
Cyclins were confirmed to could used as a therapy
marker for psoriasis. Narrow-band UV-B (NBUVB), a
commonly used means of treatment of psoriasis, could
obviously reduction the expression of keratinocyte pro-
liferation markers, Ki-67, cyclin A and cyclin B, to 62 %,
68 % and 81 %, respectively after NBUVB therapy [7].
After 6 weeks of cyclosporine therapy, a clinical im-
provement of the disease and normalization of the epi-
dermis were observed. Epidermal thickness and Ki-67-,
cyclin B- and cyclin A-positive nuclei percentage were
significantly higher before therapy than after. Whereas
cyclin D1 was negative or expressed in a low percentage
of nuclei in psoriasis before therapy [8]. Moreover, 1, 25-
dihydroxyvitamin D3 (VD3) are also used for the treat-
ment of psoriasis, and it could induce cell cycle arrest
not only at the G0/G1 phase but also at the G2/M phase
which same with our results. Further research showed
VD3 also decreased the expression of cyclin B, some dif-
ference from Psori-CM01 reduce expression of CCNB2,
VD3 decreased the expression of CCNB1, which forms
MPF complex with Cdc2 [9].
In short, our study confirmed PSORI-CM01 formula
had a good anti-psoriatic effect for its inhibit hyper-
proliferation of keratinocyte both in IMQ induced
psoriasis-form mice model in vivo, and in LPS-induced
HaCaT cell model in vitro. The molecular mechanism of
Psori-CM01 maybe related to reduce the epidermis
CCNB2 mRNA and protein expression. Cytokine storm
and negative feedback loops between cytokines and che-
mokines in psoriasis skin were thought as the main
course of psoriasis patients lesion recurrence, further re-
search of Psori-CM01 on effect of anti-inflammation
and anti-cytokines secretion in psoriasis skin, is still
needed to been carried out.
Conclusions
PSORI-CM01 inhibits epidermal hyperplasia in an
imiquimod-induced mouse model of psoriasis and re-
duces keratinocyte proliferation in vitro. Our results in-
dicate that PSORI-CM01 may possess therapeutic
potential for psoriasis by inhibiting keratinocyte prolifer-
ation through downregulation of cyclin B2.
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